Top

European Journal of Orthopaedic Surgery & Traumatology

Published in:

01-05-2013 | Original Article

Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing

Authors: Katia Sindali, Barry Rose, Hassan Soueid, Parminder Jeer, Deepak Saran, Raj Shrivastava

Published in: European Journal of Orthopaedic Surgery & Traumatology | Issue 4/2013

Abstract

Introduction

Rivaroxaban is the first licensed oral direct inhibitor of factor Xa. Recent studies from the RECORD trials suggest rivaroxaban has superior efficacy compared to enoxaparin in preventing venous thromboembolism (VTE) with no significant increase in the major bleeding risk. Concerns remain regarding the incidence of minor bleeding, consequent delayed wound healing and subsequent risk of infection. The aim of this observational study was to assess the incidence of post-operative complications in patients receiving either rivaroxaban or enoxaparin thromboprophylaxis following elective hip and knee arthroplasty.

Methods

A total of 258 patients undergoing elective total hip or knee arthroplasty within one NHS Trust were included. A total of 202 subjects (mean age, 70.7 years ± 10.0, 43 % men) received a daily dose of 10 mg of oral rivaroxaban and 56 (mean age, 70.9 years ± 9.8, 39 % men) had a daily subcutaneous injection of 40 mg of enoxaparin as thromboprophylaxis. Endpoints included VTE (deep vein thrombosis and pulmonary embolism), haemorrhagic wound complications, hospital re-admission, requirement for blood transfusion, minor and major bleeding and death.

Results

There were no significant differences in the incidence of VTE, requirement for blood transfusion and readmission rate between rivaroxaban and enoxaparin-treated patients. The incidence of minor bleeding (2.0 vs. 0 %) and haemorrhagic wound complications (5.0 vs. 1.8 %) were non-significantly higher in the rivaroxaban-treated group. There were no cases of pulmonary embolism, major bleeding or death in either group.

Conclusion

Our experience with rivaroxaban in elective hip and knee arthroplasty showed no significant difference in the incidence of VTE or major bleeding. There was, however, a tendency to greater risk of minor bleeding and wound complications that were largely haemorrhagic in nature, which may have reached significance in a larger study.

Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S–400SPubMedCrossRef

Paiement GD, Mendelsohn C (1997) The risk of venous thromboembolism in the orthopedic patient: epidemiological and physiological data. Orthopedics 20(Suppl):7–9PubMed

Cardiovascular Disease Educational and Research Trust, Cyprus Cardiovascular Disease Educational and Research Trust, European Venous Forum, International Surgical Thrombosis Forum, International Union of Angiology, Union Internationale de Phlébologie (2006) Prevention and treatment of venous thromboembolism. International consensus statement (guidelines according to scientific evidence). Int Angiol 25:101–161

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM et al (2009) Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 31(1):194–212PubMedCrossRef

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765–2775

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. The Lancet. Elsevier 372(9632):31–39CrossRef

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med 358(26):2776–2786

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. The Lancet 373(9676):1673–1680

National Institute of Clinical Excellence (NICE) (2009) TA170 Venous thromboembolism—rivaroxaban: guidance www.nice.org.uk. Cited 28 Feb 2012. Available from: http://www.nice.org.uk/TA170

10.

Atkins RM (2010) NICE and venous thromboembolism. J Bone Joint Surg Br 92(5):609–610PubMedCrossRef

11.

Jensen C, Steval A, Partington P, Reed M, Muller S (2011) Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br 93(1):91

12.

Lotke PA (2008) Rivaroxaban for thromboprophylaxis. N Engl J Med 359(20):2174; author reply 2175–3176

13.

National Intsitute of Clinical Excellence (NICE) (2010) Venous thromboembolism—reducing the risk (CG92) www.guidance.nice.org.uk. Cited 1 Mar 2012. Available from: http://guidance.nice.org.uk/CG92

14.

Cusick LA, Beverland DE (2009) The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients. J Bone Joint Surg Br 91(5):645–648PubMedCrossRef

15.

Turpie AGG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F et al (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Thromb Haemost 105(3):444–453PubMedCrossRef

16.

Byrne AM, Morris S, McCarthy T, Quinlan W, O’byrne JM (2007) Outcome following deep wound contamination in cemented arthroplasty. Int Orthop 31(1):27–31PubMedCrossRef

17.

Fender D, Harper WM, Gregg PJ (1999) Outcome of Charnley total hip replacement across a single health region in England: the results at five years from a regional hip register. J Bone Joint Surg Br 81(4):577–581PubMedCrossRef

18.

McCullagh L, Tilson L, Walsh C, Barry M (2009) A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 27(10):829–846PubMedCrossRef

19.

Turpie A, Jamal W, Schmidt A, Lassen M, Mantovani L, Kreutz R, et al (2011) XAMOS: a non-interventional study of rivaroxaban in the prophylaxis of venous thromboembolism after hip or knee surgery. J Thromb Haemost 9(Suppl 2):961

Title: Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing
Authors: Katia Sindali
Barry Rose
Hassan Soueid
Parminder Jeer
Deepak Saran
Raj Shrivastava
Publication date: 01-05-2013
Publisher: Springer-Verlag
Published in: European Journal of Orthopaedic Surgery & Traumatology / Issue 4/2013
Print ISSN: 1633-8065
Electronic ISSN: 1432-1068
DOI: https://doi.org/10.1007/s00590-012-0987-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2013

Zoran Vukasinovic (1959–2013)

Stability evaluation after isolated reconstruction of anteromedial or posterolateral bundle in symptomatic partial tears of anterior cruciate ligament

Volar long locking compression plate fixation for distal radius fractures with metaphyseal and diaphyseal extension

Glenoid or not glenoid component in primary osteoarthritis

Midterm results of combined patellofemoral and patellotibial ligaments reconstruction in recurrent patellar dislocation

Treatment of traumatic subtalar arthritis with interpositional arthroplasty with tensor fascia lata or fat